Note: The UK is no longer part of the EU regulatory system. All lifecycle activities must be managed under MHRA procedures, even where EU authorizations exist in parallel.
For initial marketing authorization, see Marketing Authorization Applications in the UK. For product information and labelling, see Product Information, Labelling & Promotional Compliance in the UK. For our full post-approval methodology across all markets, see Post-Approval & Lifecycle Management.
The UK operates an independent regulatory framework for medicinal products under the MHRA. While historically derived from EU legislation, regulatory practice has diverged in several important ways post-Brexit.
Marketing authorisations are granted and maintained through UK national procedures. All post-authorisation activities, including variations, renewals, and safety updates, are submitted directly to the MHRA.
The IRP allows the MHRA to rely on prior approvals from recognised reference regulators to support UK authorisations. It is used for both initial approvals and certain lifecycle activities.
The UK now operates separate submission pathways, timelines, and product information requirements compared to the EU.
Our UK regulatory team includes specialists in lifecycle management, IRP submissions, variation handling, and MHRA interactions.
| Activity | UK-Specific Considerations |
|---|---|
| Initial marketing authorisation | National or IRP routes |
| Variations | Independent UK submissions |
| Renewals | UK-specific process |
| Product information | UK-specific requirements |
| Lifecycle strategy | Parallel UK/EU planning |
We support integration of IRP into global strategies, manage divergence between UK and EU requirements, and deliver full lifecycle regulatory support from initial approval through post-authorisation maintenance.
Tell us about your portfolio and we will outline how we can help.
Contact UsAll regulatory activities from authorisation through post-approval maintenance, including variations and renewals.
A UK reliance pathway based on approvals from recognised regulators.
Yes, the UK operates independently from the EU.
They are submitted directly to the MHRA.
It is used for approvals but followed by standard UK lifecycle requirements.